AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-9 (Canceled).

10. (New) A lyophilized pharmaceutical composition comprising 1% to 40% by weight of rabeprazole or a salt thereof, 55% to 99% by weight of lactose, galactose, trehalose or a combination thereof and 0% to 3% by weight of other excipients.

11. (New) A lyophilized pharmaceutical composition as claimed in claim 1, comprising 1 to 30% by weight of rabeprazole or a salt thereof and 65-99% by weight of lactose, galactose, trehalose or a combination thereof.

12. (New) The lyophilized pharmaceutical composition as claimed in claim 1 wherein the other excipients are selected from the group consisting of phosphate buffer, carbonate buffer, tonicity agents and antioxidants.

13. (New) A therapy comprising delivering the lyophilized pharmaceutical composition as defined in claim 1.

14. (New) A process for preparing an injectable dosage comprising dissolving the lyophilized pharmaceutical composition as defined in claim 1 in water.

15. (New) A process for preparing a pharmaceutical composition comprising rabeprazole or a salt thereof, comprising:

a. dissolving rabeprazole or a salt thereof and lactose, galactose, trehalose or a combination thereof, with or without excipients in a solvent under stirring to form a solution;

b. adjusting the pH of the solution to 8.0-11.0

c. optionally removing any particulates from the solution; and

d. causing lyophilization of the solution.

16. (New) The process as claimed in claim 6 wherein the solvent is water.

17. (New). The process as claimed in claim 6 wherein the pharmaceutical composition contains at least 2 parts of lactose, galactose, trehalose or a combination thereof for one part of rabeprazole.

18. (New) The process as claimed in claim 6 wherein said removing any particulates comprises filtering.

19. (New) The process as claimed in claim 6 wherein lyophilization comprises primary drying at a product temperature below - 10°C and secondary drying at a temperature below 25 °C.

20. (New) The lyophilized pharmaceutical composition as claimed in claim 2 wherein the other excipients are selected from phosphate buffer, carbonate buffer, tonicity agents and antioxidants.

21. (New) A therapy comprising delivering the lyophilized pharmaceutical composition as defined in claim 2.

22. (New) A therapy comprising delivering the lyophilized pharmaceutical composition as defined in claim 3.

23. (New) A process for preparing an injectable dosage comprising dissolving the lyophilized pharmaceutical composition as defined in claim 2 in water.

24. (New) A process for preparing an injectable dosage comprising dissolving the lyophilized pharmaceutical composition as defined in claim 3 in water.

25. (New) The process as claimed in claim 7 wherein the pharmaceutical composition contains at least 2 parts of lactose, galactose, trehalose or a combination thereof for one part of rabeprazole.

26. (New) The process as claimed in claim 7 wherein said removing any particulates comprises filtering.

27. (New) The process as claimed in claim 8 wherein said removing any particulates comprises filtering.

28. (New) The process as claimed in claim 7 wherein lyophilization comprises primary drying at a product temperature below - 10°C and secondary drying at a temperature below 25 °C.

29. (New) The process as claimed in claim 8 wherein lyophilization comprises primary drying at a product temperature below - 10°C and secondary drying at a temperature below 25 °C.